Why the study?
Do PPAR agonists decrease lipoprotein lipase secretion and glycated LDL uptake in human macrophages?
Do PPAR agonists decrease lipoprotein lipase secretion and glycated LDL uptake in human macrophages?
PPAR activators decrease secreted LPL and glycated LDL uptake in human macrophages, suggesting a potential mechanism by which they could influence atherosclerosis development in diabetes.
May modulate macrophage lipid handling in animal models; leaves open translation to human atherosclerosis in diabetes.
Lipoprotein lipase (LPL) acts independently of its function as triglyceride hydrolase by stimulating macrophage binding and uptake of native, oxidized and glycated LDL. Peroxisome proliferator-activated receptors (PPARs) are nuclear receptors expressed in monocyte/macrophages, where they control cholesterol homeostasis. Here we study the role of PPARs in the regulation of LPL expression and activity in human monocytes and macrophages. Incubation of human monocytes or macrophages with PPARalpha or PPARgamma ligands increases LPL mRNA and intracellular protein levels. By contrast, PPAR activators decrease secreted LPL mass and enzyme activity in differentiated macrophages. These actions of PPAR activators are associated with a reduced uptake of glycated LDL and could influence atherosclerosis development associated with diabetes.
No takes yet. Share an insight, caveat, or question.
Gbaguidi et al. (2002) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: